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The study investigated the effects of the aldose reductase (AR) inhibitor benzofuroxane derivative 5(6)-(benzo[d]thiazol-2-
ylmethoxy) benzofuroxane (herein referred to as BF-5m) on the biochemical and tissue alterations induced by endotoxic uveitis
in rats. BF-5m has been administered directly into the vitreous, in order to assess the expression and levels of (i) inflammatory
markers such as the ocular ubiquitin-proteasome system, NF-𝜅B, TNF-𝛼, and MCP-1; (ii) prooxidant and antioxidant markers
such as nitrotyrosine, manganese superoxide dismutase (MnSOD), and glutathione peroxidase (GPX); (iii) apoptotic/antiapoptotic
factors caspases and Bcl-xl; (iv) markers of endothelial progenitor cells (EPCs) recruitment such as CD34 and CD117. 5 𝜇L of BF-
5m (0.01; 0.05; and 0.1 𝜇M) into the right eye decreased in a dose-dependent manner the LPS-induced inflammation of the eye,
reporting a clinical score 1. It reduced the ocular levels of ubiquitin, 20S and 26S proteasome subunits, NF-𝜅B subunits, TNF-𝛼,
MCP-1, and nitrotyrosine. BF-5m ameliorated LPS-induced decrease in levels of MnSOD and GPX. Antiapoptotic effects were seen
from BF-5m by monitoring the expression of Bcl-xl, an antiapoptotic protein. Similarly, BF-5m increased recruitment of the EPCs
within the eye, as evidenced by CD34 and CD117 antibodies.
1. Introduction
Uveitis, the inflammation of the uvea in the eye, is among the
leading causes of blindness and vision loss in the world [1–4].
This disease affects people of all ages, gender, and race, though
sex preponderance can be observed in some cases [3, 4]. It
also affects the working population between 20 and 59 years
[5, 6]. Because of the variability of causes, the etiology of the
uveitis is difficult to define.This pathology is characterized by
elevated levels of proinflammatory cytokines in ocular tissue,
which involve the production of inflammatorymolecules and
reactive oxygen species (ROS) [7]. The experimental animal
model closest to human uveitis is the acute form of bacterial
endotoxin, lipopolysaccharide- (LPS-) induced uveitis (EIU)
[3, 4, 8]. LPS increases the systemic expression of several
inflammatory molecules such as TNF-𝛼, IL-6, MIF, IFN-𝛾,
and MCP-1 and the production of nitric oxide. High levels of
these mediators induce, after the rupture of the blood-ocular
barrier, the infiltration of leukocytes andmonocytes in ocular
tissues promoting the development of EIU [9].
The literature reports that the inhibition of aldose reduc-
tase (AR), a key enzyme of the polyol pathway able to
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Figure 1: Chemical structure of the 5(6)-(Benzo[d]thiazol-2-ylme-
thoxy)benzofuroxane derivative BF-5m. Aldose reductase IC
50
=
0.42 ± 0.01 𝜇M in vitro.
convert the excess glucose into sorbitol with the conse-
quent formation of ROS, prevents or decreases the acute
form of the ocular inflammation induced by LPS in rats,
through decreased oxidative stress signals [10]. Various
aldose reductase inhibitors (ARIs) have been tested against
uveitis [3, 4, 7, 11–13]. We recently identified a novel class
of nonhydantoin noncarboxylic acid inhibitors, featuring the
benzofuroxane core [14, 15] as new scaffold interacting with
the so-called AR anion site. Merging submicromolar AR
inhibitory activities with significant ROS scavenging proper-
ties, these compounds could represent the ideal therapeutic
treatment for EIU being able to prevent oxidative stress-
induced inflammatory events.
For these reasons, and having in mind the presence of
the blood-ocular barrier which may limit the achievement
of therapeutic concentrations of these inhibitors within the
vitreous and chorioretina after systemic administration, we
tested the most effective compound of the whole series,
namely, 5(6)-(benzo[d]thiazol-2-ylmethoxy)benzofuroxane
(herein referred to as BF-5m), injected directly into the vitre-
ous in order to assess whether the inhibition of the local AR
ameliorates the biochemical and tissue alterations induced by
EIU.We investigated the effects that the compoundmay have
on the ocular levels of (i) inflammatory markers such as the
ocular ubiquitin-proteasome system andNF-𝜅B pathway; (ii)
prooxidant and antioxidant markers such as nitrotyrosine,
MnSOD, and GPX; (iii) proapoptotic/antiapoptotic factors
caspases and Bcl-xl protein; (iv) markers of endothelial
progenitor cells (EPCs) recruitment such as CD34 and
CD117.
2. Materials and Methods
2.1. Drug. BF-5m, 5(6)-(benzo[d]thiazol-2-ylmethoxy)ben-
zofuroxane (Figure 1), was synthesized at the Department of
Pharmacy of the University of Pisa, Italy, following a previ-
ously reported procedure [15]. Briefly, alkylation of the com-
mercially available 4-amino-3-nitrophenol with chloroace-
tonitrile, in the presence of anhydrous potassium car-
bonate, provided the 2-(4-amino-3-nitrophenoxy) acetoni-
trile which, through reaction with o-aminothiophenol, gave
the key intermediate 4-[(benzo[d]thiazol-2-yl)methoxy]-2-
nitrobenzenamine. Treatment with sodium nitrite in con-
centrated hydrochloric acid, and then with sodium azide
in water, gave the corresponding azido-derivative, which
cyclized to the target inhibitor, 5(6)-(benzo[d]thiazol-2-
ylmethoxy) benzofuroxane, when heated under reflux in an
acetic acid solution.
2.2. Induction of EIU. Male Sprague-Dawley rats (Harlan,
Italy) (420–450 gr) were injected subcutaneously into the
footpad with 200𝜇g of lipopolysaccharide (LPS, Salmonella
minnesota, Sigma St Louis, MO, USA) in 0.1mL of sterile
pyrogen-free saline for induction of EIU. 1 h after LPS
injection, under pentobarbital anaesthesia (45mg/kg i.p. in
saline), the pupils were dilated by instillation of one drop
of tropicamide 5%; then local anaesthesia was induced with
one drop of tetracaine 1% followed by intravitreal injection of
the tested compound in the right eye. This was executed by
using sterile syringes fitted with a 30-gauge needle (Micro-
fine, BD, Italy) and 5 𝜇L [16] of three different BF-5m concen-
trations, 0.01, 0.05, and 0.1 𝜇M, in the range used in previous
studies [15].The compound was reconstituted in 1% dimethyl
sulfoxide (DMSO, Sigma, Italy) 2 h prior to LPS injection
and injected into the vitreous 1 h after LPS. The following 6
experimental groups were considered (𝑛 = 6 for each group):
vehicle (saline); vehicle (1%DMSO); LPS+saline; LPS+BF-5m
(0.01; 0.05; 0.1 𝜇M/rat). Rats were killed 24 h after treatment
and evaluated for clinical signs and biochemical markers. All
the procedures were approved by the local Ethic Committee,
number 2108/12.
2.3. Clinical Score Attributed to EIU. The development of
uveitis was determined 24 h after the administration of the
compound following themethod reported by Rossi et al. [17].
The clinical signs of uveitis were scored from 0 to 4, and
uveitis was considered positive when the score assigned was
>1.
2.4. Eye Samples. Harvested eyes were cut in two halves: one
half was immediately frozen in liquid nitrogen for the bio-
chemical assays, and the other half was immediately fixed by
immersion in 10% buffered formalin and paraffin-embedded
for immunohistochemistry, as previously described [17].
2.5. Western Blotting Assay. Western blot technique was
performed in agreement with our previous work [17]. The
primary antibodies used were antiproteasome subunits (Fl-
76, anti-20S, and anti-26S), anti-NF-𝜅B p65 (C-20), anti-NF-
𝜅B p50 (H-119) and p105 (H-119), anti-glutathione peroxidase
(GPX), anti-manganese-superoxide dismutase (Mn-SOD),
and anti-Bcl-xl. These primary antibodies were purchased
from Santa Cruz Biotec (USA). Secondary antibodies were
conjugated with HRP horseradish peroxidase, donkey poly-
clonal to rabbit IgG, goat anti-mouse, and goat anti-rabbit,
and were all purchased from Santa Cruz Biotec (USA).
Results are expressed in densitometric units.
2.6. ELISA Assay. A commercial colorimetric ELISA kit
(R&D systems, USA) was used to quantitatively assay the
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Figure 2: Clinical score attributed to EIU after intravitreal BF-5m. Sprague-Dawley rats were treated with vehicle (saline), LPS (200𝜇g/rat),
vehicle (1% DMSO), and LPS+BF-5m (0.01; 0.05; 0.1 𝜇M/rat) 1 h following LPS treatment and were evaluated 24 h after injections. Clinical
score to EIU has been reported in the test (see Material and Methods). Values are mean ± SEM, of 𝑛 = 6 observation for each experimental
group. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 compared with LPS-treated group; ∘𝑃 < 0.01 versus vehicle saline group.
levels of ocular tumor necrosis alpha (TNF-𝛼) and monocyte
chemoattractant protein-1 (MCP-1) according to the manu-
facturer’s instructions. 200𝜇L of eye homogenate was used.
Briefly, frozen tissueswere homogenized in PBSwith protease
inhibitors, added of Triton X-100 to a final concentration of
1% and centrifuged for 5min at 10,000×g at 4∘C.
2.7. Immunohistochemistry. Antinitrotyrosine antibodies were
used for evaluating oxidative stress and CD117 and CD34
antibodies for recruitment of EPCs (Santa Cruz Biotec, USA).
The ocular tissues were incubated with specific primary
antibodies, washed in PBS, and incubated with secondary
antibody. The ocular samples were analyzed by an expert
pathologist (variability 6%); every sample was visualized at
200x magnification. The number of CD34+, CD117+, and
nitrotyrosine positive particles per area was analyzed in 20
microscopic fields under 200x.
2.8. RNA Extraction and RT-PCR. Total RNA was extracted
from homogenized eye using an RNA Tri-Reagent (Molecu-
lar Research Center Inc., Cincinnati, OH) according to the
manufacturer’s protocol. The extracted RNA was subjected
to DNase I treatment at 37∘C for 30min. The total RNA
concentration was determined by UV spectrophotometer.
The mRNA levels were measured by RT-PCR amplification,
as previously reported [18]. RT minus controls were carried
out to check potential genomic DNA contamination. These
RTminus controls were performed without using the reverse
transcriptase enzyme in the reaction mix. Sequences for
the rat mRNAs from GeneBank (DNASTAR INC., Madi-
son, WI) were used to design primer pairs for RT-PCRs
(OLIGO 4.05 software, National Biosciences Inc., Plymouth,
MN). Each RT-PCR was repeated at least three times to
achieve best reproducibility data. The measured mRNA
levels were normalisedwith respect to hypoxanthine-guanine
phosphoribosyl transferase (HPRT), chosen as housekeeping
gene. The HPRT gene expression did not change in several
experimental conditions [18]. To our knowledge there is no
molecular evidence for variation in HPRT mRNA-levels in
this model. The gene expression values were expressed as
arbitrary units ± SE. Amplification of genes of interest and
HPRT was performed simultaneously. PCR products were
resolved into 2.0% agarose gel. A semiquantitative analysis
of mRNA levels was carried out by the Gel Doc EZ UV
System (Bio-Rad, Hercules, CA). Total RNA was extracted
from the eye of vehicle-, LPS- and BF-5m-treated rats and
reverse transcribed into cDNA using Superscript reverse
transcriptase system.The expression of caspase 3 and caspase
8 was quantified by qPCR using commercially available rat
primers. HPRT was used as internal control. Results are
expressed as arbitrary units based on calculation of 2−ΔΔCt
method. Relative amount of target genes were normalized to
HPRT and to vehicle.
2.9. Statistical Analysis. Data are expressed as means ±
standard error of themean (SEM). Student’s 𝑡-test (when only
two groups were compared) or one-way ANOVA followed
by Dunnett’s test (more than two experimental groups) was
used. 𝑃 < 0.05 was considered statistically significant.
3. Results
3.1. Effects of BF-5m on EIU Clinical Score. LPS-injected rats
showed alterations of vascular intermediate membrane of the
eye with a clinical score of 4 (Figure 2). BF-5m injected into
the vitreous at three different concentrations (0.01; 0.05; and
0.1 𝜇M) decreased the LPS-induced inflammation of this eye
in a dose-dependent manner, reporting a clinical score 1.1
(Figure 2).
3.2. BF-5m and EIU InflammatoryMarkers. Western blotting
analysis revealed the highest expression ofmarkers of inflam-
mation such as ubiquitin, 20S and 26S proteasome subunits,
and NF-𝜅B subunits in the eyes following LPS treatment.
These markers were significantly and dose-dependently
reduced by BF-5m.The tested compound expressed maximal
action at the concentration of 0.1 𝜇M (Figures 3 and 4). 0.01
and 0.05 𝜇M BF-5m had less effects on proteasome and NF-
𝜅B (Figures 3 and 4).
In addition, ELISA showed a dose-dependent reduction
of the ocular levels of the cytokine TNF-𝛼 and of the
chemokine MCP-1 following intravitreal BF-5m compared
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Figure 3: Western blotting analysis for ubiquitin, proteasome 20S, and proteasome 26S subunits. Injection of BF-5m (0.01; 0.05; 0.1 𝜇M/rat)
into the vitreous of LPS-treated rats dose-dependently reduced the expression of ubiquitin (a), protesome 20S (b), and proteasome 26S (c).
Results are expressed as densitometric units and represented the mean ± SEM of 𝑛 = 6 observations for each group. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01
versus LPS-treated rats; ∘𝑃 < 0.01 versus vehicle saline group.
with the levels expressed into the ocular tissue of LPS-treated
animals (Figure 5).
3.3. BF-5mAffects the Oxidative Stress Induced by EIU. Inves-
tigation on eye tissue homogenates of rats with EIU showed
significantly decreased levels of MnSOD (−44%) and GPX
(−40%) induced by LPS with respect to the vehicle (saline)
group (Figure 6). These decreases were almost completely
abolished by intravitreal injection of BF-5m,with amaximum
effect onMnSOD (42%) andGPX (36%) expression at 0.1 𝜇M
concentration (Figure 6).
To define oxidative damage within the eyes of EIU rats
treated with BF-5m, immunohistochemistry was used to
evaluate the nitrotyrosine expression 24 h after LPS injection,
time required for developing the acute phase of inflam-
mation. The expression of nitrotyrosine that was mainly
localized into the ciliary bodies and choroid augmented
significantly in the eyes of LPS group (Figures 7 and 8).
Treatment with BF-5m significantly reduced the expression
of this marker with respect to vehicle alone (Figures 7
and 8). Interestingly, this reduction induced by BF-5m was
paralleled by increased expression of CD34 and CD117,
markers of EPCs recruitment into the eye (Figures 7 and
8).
3.4. Antiapoptotic Effects of BF-5m. Bcl-xl, an antiapop-
totic protein, showed slightly appreciable expression in eyes
homogenates of EIU rats, while its expression was much
stronger in ocular tissue of rats treatedwith BF-5m (Figure 9).
In contrast, mRNAs for caspase 3 and caspase 8 were reduced
by BF-5m (Figure 10).
4. Discussion
Here we show that the AR inhibitor BF-5m was able to
decrease the clinical signs of endotoxic uveitis, an effect that
was associated to diminution of the nitrotyrosine and to
an increased expression of the antioxidant proteins MnSOD
and GPX within the eye. Furthermore, BF-5m decreased
the expression of the ubiquitin, 20S and 26S proteasome
subunits in uveitic eyes, highlighting that, in addition to stress
lowering activities, BF-5m also may lower the deleterious
effect that the proinflammatory ubiquitin-proteasome system
may have on the integrity of eye structures. As a major
system for nonlysosomal intracellular protein degradation
in eukaryotic cells, it is involved in a number of biological
processes, including inflammation, proliferation, and apop-
tosis, that are responsible for the disease progression and
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Figure 4: Western blotting analysis for NF-𝜅B. Injection of BF-5m (0.01; 0.05; 0.1𝜇M/rat) into the vitreous 24 h after LPS-treatment of the
rats reduced the expression of activated NF-𝜅B 105 (a), p50 (b), and p65 (c). Results are expressed as densitometric units and represented the
mean ± SEM of 𝑛 = 6 observations for each group. ∘𝑃 < 0.01 versus vehicle saline group ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus LPS-treated rats.
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Figure 5: Ocular levels of tumor necrosis factor alpha (TNF-𝛼) and monocyte chemoattractant protein-1 (MCP-1) within the tissue of rats
with EIU, evaluated 24 h after the administration of vehicle (saline), vehicle (DMSO), LPS (200𝜇g/s.c.), or LPS+BF-5m (0.01; 0.05; 0.1 𝜇M/rat)
into the vitreous.The values are expressed as mean ± SEM of 𝑛 = 6 observations for each group. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus LPS-treated
rats; ∘𝑃 < 0.01 versus vehicle saline group.
associate with poor prognosis [19].The ubiquitin-proteasome
system is required for activation of nuclear factor kappa
B (NF-𝜅B), a central transcription factor that regulates
inflammatory genes, by degradation of its inhibitory kappa
B (I𝜅B) proteins [20], and a series of downstream events
leading to the development of the inflammatory responses
within organs and tissues. Here, the reduction of ubiquitin-
proteasome subunits by BF-5m was accompanied by reduced
expression of NF-𝜅B in the eyes of EIU rats. Consequently,
the levels of proinflammatory factors TNF-𝛼 and MCP-1 and
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Figure 6: Western blotting analysis for Mn-SOD and GPX. Expression of manganese superoxide dismutase (Mn-SOD) (a) and glutathione
peroxidase (GPX) (b) into the vitreous of rats 24 h after treatment with LPS or LPS+BF-5m (0.01; 0.05; 0.1 𝜇M/rat) compound. Densitometric
units as calculated from WB traces are expressed as mean ± SEM of 𝑛 = 6 observations for each group. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus
LPS-treated rats; ∘𝑃 < 0.01 versus vehicle saline group.
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Figure 7: Representative immunohistochemistry for nitrotyrosine, CD117-ckit, and CD34 in the eye structures of rats treated with
vehicle, LPS, and BF-5m (0.05 𝜇M/rat). Intravitreal BF-5m increases CD34+ and CD117+ immunostaining into the eye, while reducing the
nitrotyrosine. Nitro: nitrotyrosine; R: retina; Ch: choroid; Cb: ciliary bodies. Scale bar, 50𝜇m. 200x magnification.
the proapoptotic [21] caspase 3 and caspase 8 were dimin-
ished.Therefore, inhibition of the local AR by BF-5m reduces
the stress-induced inflammatory component of the uveitis.
The compound also increased the expression of two cell sur-
vival and proliferation markers, the CD34 and CD117, within
the ocular tissue. CD117 is a transmembrane tyrosine kinase
receptor, also called c-KIT, which involves the development
and survival of hematopoietic stem cells, melanocytes, germ
cells, mast cells, and interstitial cells of Cajal [22]. CD34 is a
marker of stem cells; it is a member of a family of single-pass
Mediators of Inflammation 7
0
250
500
750
CD
3
4
nu
m
be
r o
f p
os
iti
ve
 p
ar
tic
le
s
×
to
ta
l a
re
a
Vehicle
saline
LPS Vehicle
DMSO
0.01 0.05 0.1
LPS +BF-5m
∗
∗∗
∗∗
(a)
0
250
500
750
CD
1
1
7
nu
m
be
r o
f p
os
iti
ve
 p
ar
tic
le
s
×
to
ta
l a
re
a
Vehicle
saline
LPS Vehicle
DMSO
0.01 0.05 0.1
LPS +BF-5m
∗
∗∗
∗∗
(b)
0
250
500
750
N
itr
ot
yr
os
in
e n
um
be
r o
f p
os
iti
ve
pa
rt
ic
le
s ×
to
ta
l a
re
a
Vehicle
saline
LPS Vehicle
DMSO
0.01 0.05 0.1
LPS +BF-5m
∗
∗∗
∗∗
∘
(c)
Figure 8: Number of CD34+, CD117+, and nitrotyrosine positive particles per area analyzed by immunohistochemistry. 20 microscopic fields
were counted under 200x magnification in vehicle, LPS, and LPS+BF-5m 0.01; 0.05; 0.1 𝜇M/rat. Values are mean ± SEM of 𝑛 = 6 observations
for each group. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus LPS-treated group; ∘𝑃 < 0.01 versus vehicle saline group.
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Figure 9:Western blotting for Bcl-xl. Expression of the antiapoptotic protein Bcl-xl in eye tissue of rats treated with LPS or LPS+BF-5m (0.01;
0.05; 0.1 𝜇M/rat). Values are mean ± SEM of 𝑛 = 6 observations for each group. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus LPS-treated rats; ∘𝑃 < 0.01
versus vehicle (saline) group.
transmembrane proteins that functions as a factor in cell-cell
adhesion [23]. Literature data reported that the expression of
these markers is stimulated after numerous insults including
oxidative stress and inflammation [24, 25] and is aimed at
signalizing starting repair of damaged tissue by the EPC
recruited to the insulted site. Therefore, although further
insights are needed, BF-5m by increasing the recruitment
of EPCs into the eye may facilitate the initiation of EIU
resolution.
In conclusion, this study shows that the benzofurox-
ane derivative BF-5m represents a new opportunity for
drug intervention aimed at preventing EIU development. It
improves the immune-inflammatory profile of the rat eye.
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Figure 10: RT-PCR analysis for caspase 3 and caspase 8. Caspase 3 and caspase 8 in ocular tissue following treatment with BF-5m (0.01; 0.05;
0.1 𝜇M/rat). Total RNA was extracted from the eye of vehicles, LPS, and BF-5m rats and reverse transcribed into cDNA using Superscript
reverse transcriptase system. The expression of caspase 3 and caspase 8 was quantified by qPCR using commercially available rat primers.
HPRT was used as internal control. Results are expressed as arbitrary units based on calculation of 2−ΔΔCt method. Relative amount of target
genes were normalized to HPRT and to vehicle. Results are expressed as the mean ± SEM of 𝑛 = 6 observations for each group. ∗𝑃 < 0.05
and ∗∗𝑃 < 0.01 versus LPS-treated rats; ∘𝑃 < 0.01 versus vehicle saline group.
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